PL447910A1 - Nowe zastosowanie medyczne pochodnych 4-arylo-1-(4-metyloimidazo-5-ilo) tiosemikarbazydu - Google Patents
Nowe zastosowanie medyczne pochodnych 4-arylo-1-(4-metyloimidazo-5-ilo) tiosemikarbazyduInfo
- Publication number
- PL447910A1 PL447910A1 PL447910A PL44791024A PL447910A1 PL 447910 A1 PL447910 A1 PL 447910A1 PL 447910 A PL447910 A PL 447910A PL 44791024 A PL44791024 A PL 44791024A PL 447910 A1 PL447910 A1 PL 447910A1
- Authority
- PL
- Poland
- Prior art keywords
- meta
- derivatives
- methylimidazo
- aryl
- para
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
- C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Zgłoszenie rozwiązuje problem aktywności i nowego zastosowania pochodnych imidazolotiosemikarbazydu do zwalczania infekcji wywołanych przez dermatofity, gdzie aktywność ta jest korzystniejsza od stosowanych leków azolowych. Istota wynalazku dotyczy nowego zastosowania pochodnych imidazolotiosemikarbazydu o wzorze 1 przedstawionym na rysunku, gdzie R1 oznacza podstawnik meta-jodowy, meta-bromowy, orto-nitrowy, meta-nitrowy, para-nitrowy, orto-metylowy, meta-metylowy, para-metylowy, para-acetylowy do zwalczania infekcji wywołanych przez dermatofity porównywalną do stosowanych leków azolowych. Korzystnie pochodne te stosuje się do wytwarzania leku przeznaczonego do zwalczania infekcji dermatofitowych.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL447910A PL447910A1 (pl) | 2024-03-01 | 2024-03-01 | Nowe zastosowanie medyczne pochodnych 4-arylo-1-(4-metyloimidazo-5-ilo) tiosemikarbazydu |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL447910A PL447910A1 (pl) | 2024-03-01 | 2024-03-01 | Nowe zastosowanie medyczne pochodnych 4-arylo-1-(4-metyloimidazo-5-ilo) tiosemikarbazydu |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL447910A1 true PL447910A1 (pl) | 2025-09-08 |
Family
ID=96946638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL447910A PL447910A1 (pl) | 2024-03-01 | 2024-03-01 | Nowe zastosowanie medyczne pochodnych 4-arylo-1-(4-metyloimidazo-5-ilo) tiosemikarbazydu |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL447910A1 (pl) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL426156A1 (pl) * | 2018-06-29 | 2020-01-02 | Uniwersytet Medyczny W Lublinie | Pochodne 4-jodofenylo-1-(4-metyloimidazol-5-ilo)tiosemikarbazydu, sposób ich wytwarzania i zastosowanie medyczne |
-
2024
- 2024-03-01 PL PL447910A patent/PL447910A1/pl unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL426156A1 (pl) * | 2018-06-29 | 2020-01-02 | Uniwersytet Medyczny W Lublinie | Pochodne 4-jodofenylo-1-(4-metyloimidazol-5-ilo)tiosemikarbazydu, sposób ich wytwarzania i zastosowanie medyczne |
Non-Patent Citations (4)
| Title |
|---|
| BEKIER, A ET AL.: "Cells. 2021 Dec 9; 10(12): 3476", IMIDAZOLE-THIOSEMICARBAZIDE DERIVATIVES AS POTENT ANTI-MYCOBACTERIUM TUBERCULOSIS COMPOUNDS WITH ANTIBIOFILM ACTIVITY. * |
| DALLA LANA, DF ET AL.: "J Appl Microbiol. 2015; 119(2): 377-88", IMIDAZOLIUM SALTS WITH ANTIFUNGAL POTENTIAL AGAINST MULTIDRUG-RESISTANT DERMATOPHYTES. * |
| PANETH, A ET AL.: "Molecules. 2019 Apr 24;24(8):1618", DISCOVERY OF POTENT AND SELECTIVE HALOGEN-SUBSTITUTED IMIDAZOLE-THIOSEMICARBAZIDES FOR INHIBITION OF TOXOPLASMA GONDII GROWTH IN VITRO VIA STRUCTURE-BASED DESIGN. * |
| PANETH, A. ET AL.: "Molecules. 2019; 24(3): 614", SYSTEMATIC IDENTIFICATION OF THIOSEMICARBAZIDES FOR INHIBITION OF TOXOPLASMA GONDII GROWTH IN VITRO. * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Awasthi et al. | SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents | |
| Al-Abdullah et al. | Synthesis, antimicrobial, and anti-inflammatory activity, of novel S-substituted and N-substituted 5-(1-adamantyl)-1, 2, 4-triazole-3-thiols | |
| Fletcher et al. | Antimicrobial 1, 3, 4-trisubstituted-1, 2, 3-triazolium salts | |
| Xie et al. | Design, synthesis, and in vitro evaluation of novel triazole analogues featuring isoxazole moieties as antifungal agents | |
| BRPI0413051A (pt) | compostos de indazol 3,5-dissubstituìdos, composições farmacêuticas e métodos para mediar ou inibir a proliferação celular | |
| Yousef et al. | Sulfonamides: historical discovery development (structure-activity relationship notes) | |
| BG105801A (bg) | 1 - хетероциклични заместени диариламини | |
| Tiwari et al. | 1, 3, 4‐oxadiazole derivatives as potential antimicrobial agents | |
| Yan et al. | Opportunities and challenges of using five‐membered ring compounds as promising antitubercular agents | |
| JP4988204B2 (ja) | 筋萎縮性側索硬化症(als)又はalsに起因する疾患の新規治療剤 | |
| Nascimento et al. | A novel tetrasubstituted imidazole as a prototype for the development of anti-inflammatory drugs | |
| Yadav et al. | Synthesis, anti-HIV, antimicrobial evaluation and structure activity relationship studies of some novel benzimidazole derivatives | |
| Roy et al. | Synthesis and biological evaluation of substituted 4-arylthiazol-2-amino derivatives as potent growth inhibitors of replicating Mycobacterium tuberculosis H37RV | |
| Zhang et al. | 2, 4, 5-Trisubstituted imidazoles: novel nontoxic modulators of P-glycoprotein mediated multidrug resistance. Part 2 | |
| MA27677A1 (fr) | Azoles, procedes pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation | |
| Feng et al. | Selective synthesis of sulfonamides and sulfenamides from sodium sulfinates and amines | |
| PL447910A1 (pl) | Nowe zastosowanie medyczne pochodnych 4-arylo-1-(4-metyloimidazo-5-ilo) tiosemikarbazydu | |
| Vashisht et al. | Antimicrobial activity of isoxazole derivatives: A brief overview | |
| Scarim et al. | An overview of sulfonamide‐based conjugates: Recent advances for tuberculosis treatment | |
| Daraji et al. | Structure based design, synthesis, and biological evaluation of imidazole derivatives targeting dihydropteroate synthase enzyme | |
| Ridahunlang et al. | Isoniazid derivatives as anti-tubercular agents: From structural design to clinical investigations | |
| Zhu et al. | Synthesis and pharmacological evaluation of mono-arylimidamides as antileishmanial agents | |
| Sivakumar et al. | 5-imidazolinone derivatives as a potent pharmacological agents—A review | |
| Sediek et al. | Synthesis, antimicrobial activity, and biofilm inhibition studies of 1, 2, 3-triazole-containing 2, 3-dihydrothiazole | |
| Sable et al. | Furan–thiazole hydrazone scaffolds as promising antitubercular and antibacterial agents: synthesis, characterization, bioevaluation and computational analysis |